Your session is about to expire
← Back to Search
MRI for Diagnosing Osteoradionecrosis in Head and Neck Cancer
N/A
Recruiting
Led By Stephen Lai
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
COHORT 2 (ENRICHED): Subjects with recurrent and/or new head and neck cancer disease who will undergo re-irradiation to the head and neck with intent to eradicate the malignancy. Treatment criteria specified
COHORT 3 (EARLY ORN INTERVENTION): Subjects with clinically confirmed low-grade/early stage osteoradionecrosis requiring therapeutic intervention as diagnosed by a qualified clinician. Clinical staging criteria specified
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
Study Summary
This trial uses MRI to study how well it can diagnose osteoradionecrosis in patients with head and neck cancer undergoing radiation therapy.
Who is the study for?
This trial is for patients with head and neck cancer, either new or recurrent, who are undergoing radiation therapy. Participants must be willing to consent and follow study procedures throughout the duration. They should have a good performance status (able to carry out daily activities) and not have been diagnosed with osteoradionecrosis at enrollment. Exclusions include poor kidney function, claustrophobia, pregnancy, cognitive impairment, non-MRI compatible implants, or previous multiple radiotherapies for head and neck malignancies.Check my eligibility
What is being tested?
The trial is testing how well dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can predict bone damage caused by radiation therapy in patients with head and neck cancer. It involves different groups: those about to start radiation therapy; those already treated; those showing early signs of bone damage; and those needing surgery due to severe bone damage.See study design
What are the potential side effects?
Potential side effects mainly relate to MRI procedure discomforts such as reactions to contrast agents used during DCE-MRI (like mild allergic reactions), feelings of claustrophobia inside the MRI machine, or issues related to lying still during the scan.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have recurring or new head and neck cancer and will undergo more radiation to try to cure it.
Select...
I have early stage bone damage from radiation needing treatment.
Select...
I have received radiation therapy aimed at curing my cancer, with or without chemotherapy.
Select...
I am able to care for myself and perform daily activities.
Select...
I am about to start or am currently receiving radiation, with or without chemotherapy, to try to cure my cancer.
Select...
I need surgery for severe bone damage from radiation.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
DCE-MRI Derived Parameters Following External Beam Radiation Therapy (EBRT) and Subsequent Development of Osteoradionecrosis (ORN)
Secondary outcome measures
Dose-Response Relationships Between DCE-MRI Derived Imaging Biomarkers and Subsequent Development of Osteoradionecrosis (ORN)
Side effects data
From 2013 Phase 2 trial • 44 Patients • NCT0022776011%
Dyspnea
7%
Headache
5%
Infection and infestations - other
5%
Chest pain - cardiac
5%
Back pain
5%
Dehydration
5%
Myocardial infarction
2%
Hypoxia
2%
Seizure
2%
Chest wall pain
2%
Vascular disorder - other
2%
Thromboembolic event
2%
Syncope
2%
Fatigue
100%
80%
60%
40%
20%
0%
Study treatment Arm
Treatment (Cediranib Maleate)
Trial Design
4Treatment groups
Experimental Treatment
Group I: Cohort 4 (DCE-MRI)Experimental Treatment2 Interventions
Patients undergo DCE-MRI within 4 weeks prior to and at 5-10 weeks and 12 months post surgery.
Group II: Cohort 3 (DCE-MRI)Experimental Treatment2 Interventions
Patients undergo DCE-MRI before and at 2 and 6 months post ORN treatment. Patients may undergo DCE-MRI during the mid-ORN treatment.
Group III: Cohort 2 (DCE-MRI)Experimental Treatment2 Interventions
Patients undergo DCE-MRI within 4 weeks prior to the first re-radiation fraction, within 3-5 weeks after radiation start, and at 2, 6, 12, 24, and 36 months post radiation.
Group IV: Cohort 1 (DCE-MRI)Experimental Treatment2 Interventions
Patients with newly diagnosed tumors undergo DCE-MRI within 4 weeks prior to the first radiation fraction, within 3-5 weeks after radiation start, and at 2, 6, 12, 24, and 36 months post radiation. Patients who were previously irradiated and are at various stages of oncologic follow-up undergo DCE-MRI for a total of 2-5 times at baseline and at 6, 12, 24, 36, and/or 48 months post radiation. Patients in the third or subsequent years post treatment may undergo subsequent yearly imaging studies.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dynamic Contrast-Enhanced Magnetic Resonance Imaging
2006
Completed Phase 2
~310
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,654 Previous Clinical Trials
40,931,753 Total Patients Enrolled
M.D. Anderson Cancer CenterLead Sponsor
2,966 Previous Clinical Trials
1,803,381 Total Patients Enrolled
National Institute of Dental and Craniofacial Research (NIDCR)NIH
300 Previous Clinical Trials
847,212 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I cannot get clear scans to check for specific cancer markers.I had radiotherapy for cancer in my head or neck, not including skin cancer.I had radiotherapy for cancer, with or without chemotherapy.I have recurring or new head and neck cancer and will undergo more radiation to try to cure it.I have early stage bone damage from radiation needing treatment.My kidney function is reduced with a GFR less than 60.I have had radiotherapy for head or neck cancer more than once, not including skin cancer.I have received radiation therapy aimed at curing my cancer, with or without chemotherapy.I am able to care for myself and perform daily activities.I am about to start or am currently receiving radiation, with or without chemotherapy, to try to cure my cancer.I need surgery for severe bone damage from radiation.My cancer diagnosis was confirmed through a tissue sample.
Research Study Groups:
This trial has the following groups:- Group 1: Cohort 2 (DCE-MRI)
- Group 2: Cohort 4 (DCE-MRI)
- Group 3: Cohort 3 (DCE-MRI)
- Group 4: Cohort 1 (DCE-MRI)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are enrollment opportunities still available for this experiment?
"Indeed, clinicaltrials.gov reflects that this trial is currently recruiting participants since its posting on March 21st 2017 and later update in December 5th 2022. The study requires a total of 1400 patients from 1 site."
Answered by AI
How many individuals have enrolled in this experiment?
"Affirmative. Clinicaltrials.gov's data reveals that the medical study, which was initiated on March 21st 2017 is still searching for participants. 1400 patients must be admitted at a single site to complete the trial."
Answered by AI
Share this study with friends
Copy Link
Messenger